Amid Legal Risks, This Company Is Still Rated a Buy
PACS Group shares have rebounded after a Medicare billing scandal, with strong Q2 earnings and Buy ratings, though DOJ and SEC investigations and shareholder lawsuits remain unresolved.
When investors look forstocks riding the aging of America, they might look at hospital chains, pharmacy benefit managers, or dividend-paying healthcare REITs. PACS Group Today$43. 88-0. 44 (-1. 00%)As of 08/18/2026 03:59 PM EasternThis is a fair market value price provided by Massive. Learn more. 52-Week Range$7. 50▼$49. 49P/E Ratio25. 51Price Target$56. 00What few might expect isPACS GroupNYSE: PACS, a skilled nursing operator whose stock fell more than 80% in a year after a short seller accused it of gaming Medicare, it delayed financial reports, a federal investigation began, and its chief financial officer was replaced. Now, less than two years later, analysts rate the company a Buy. With the stock having fully rebounded, investors might want to consider whether PACS is one of the market's more improbable comebacks with room to run, or whether legal risks are still clouding its future. GetPACS Groupalerts:A Stunning Rise Followed by a CollapsePACS went public in April 2024 in a $450 million IPO at $21 per share, which valued it above $3 billion. Within seven months, it had more than doubled. That’s when short sellerHindenburg Research accused the companyof fueling its growth with aggressive Medicare billing. The stock would soon crater amid federal investigations, delayed earnings and an accounting restatement. PACS Group, Inc. (PACS) Price Chart for Wednesday, August, 19, 2026Shares eventually bottomed at $7. 50 in 2025, soon after the company’s chief financial officer resigned after it was found that he had accepted gifts from business partners. The Numbers Behind the RallySince then, however, the company’s performance has maintained momentum. And the case for the comeback got even stronger in August, when PACS reported this year’s second-quarter results. The company saidrevenue rose 9. 1% year-over-year to $1. 43 billion, beating the $1. 41 billion Wall Street expected. Net income jumped 49. 8%, to $76. 3 million, while diluted earnings per share (EPS) climbed 51. 6%, to 47 cents. Adjusted EPS of 63 cents topped analysts’ consensus by 9 cents. The numbers underneath the results were equally strong. Adjusted earnings before interest, taxes, depreciation, amortization, and rent (EBITDAR) margin expanded 150 basis points, from 10. 2% to 11. 7%. Same-store skilled nursing revenue grew 5. 8%, and the company treated a richer mix of higher-acuity patients, it said. Management liked what it saw enough to raise full-year guidance to between $5. 75 billion and $5. 85 billion in revenue and $640 million to $660 million in adjusted EBITDA, both increases from prior targets. That built on a 2025 in which revenue grew 29. 3%, to $5. 3 billion, with net income reaching $191. 5 million. Growth Accelerates in a Fragmented MarketPACS's results show the impact of playing in a fragmented industry that continues to face more demand than supply. Already one of the largest skilled nursing platforms in the country, PACS subsidiaries run 344 post-acute care facilities across 17 states, serving more than 33,400 patients daily. Further,PACS agreed in June to acquire 34 skilled nursing facilitieswith 3,633 beds from Eduro Healthcare across six western states. With a healthy balance sheet, the growth can continue. The company reported more than $700 million of available liquidity, including $164. 5 million of cash, at quarter's end. Analysts See More Upside AheadWall Street has taken notice. Seven analysts carry a consensusBuy ratingon the stock, with one Strong Buy, five Buy and one Hold. The company carries an average 12-month price target of $56 against a recent price of about $44, implying roughly a 25% upside. UBS, RBC, Oppenheimer, and Truist all raised their targets after the earnings, while Zacks Research lifted its recommendation from a Hold to a Strong Buy. Legal and Regulatory Risks RemainThe most obvious reason for caution, however, is the one the earnings report can't fix. The Department of Justice has multiple ongoing investigations into PACS, examining potential False Claims Act violations tied to Medicare billing, Anti-Kickback Statute referral practices, pandemic-era waiver claims and allegedly false statements to the government. The company also disclosed that it is under investigation by the Securities and Exchange Commission related to its accounting and financial reporting and disclosure. PACS, for its part, said it cannot estimate timing or financial impact. In addition, a securities fraud class action covering shareholders who bought stock between April and December 2024 remains active, and another law firm announced a fresh shareholder investigation into the board in July. Insider activity has also been active. Corporate insiders own roughly 70% of shares, which could read as a vote of confidence, yet they also sold more than $39 million in stock over the past 12 months. A Riskier Way Into a Steady TrendFor all these reasons, PACS might be best understood as a leveraged bet on a demographic trend that at the same time is also broadly lifting other skilled nursing names, such asThe Ensign GroupNASDAQ: ENSG,The Pennant GroupNASDAQ: PNTG, andNational HealthCareNYSEAMERICAN: NHC. There’s no doubt for the industry that the aging-population tailwind is real and durable. Whether PACS can keep compounding depends entirely on outcomes outside its earnings power. With multiple investigations still open and no timeline for their closure, investors will find out the answer one way or the other. Continue following MarketBeatAdd MarketBeat as your preferred source on Google to see our latest stories in your feed. Should You Invest $1,000 in PACS Group Right Now?Before you consider PACS Group, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified thefive stocksthat top analysts are quietly whispering to their clients to buy now before the broader market catches on. . . and PACS Group wasn't on the list. While PACS Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks HereThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important. Get This Free Report